market situation. This is significant since there is currently no reliable central database in Germany which lists DS in time. The kind of DS in the hospital setting demands a rapid and focused management in order to ensure continuity of care.

Purpose Our aim was to develop a method to provide internal transparency over DS affecting our clinic (a 1600-bed maximum acute care facility), to cooperate with the physicians for a proper and efficient decision flow, and to adapt correspondingly to the drug-supply chain (DSC).

Material and methods We created a colour-coded algorithm on how to react to DS, depending on certain factors:

1. Yellow/orange: Therapeutic alternative is available. Consider brief information for the affected units.
2. Red: Therapeutic alternative is available but with relevant changes (e.g. import, internal compounding in the pharmacy), there is a very limited supply or no drug left at all. Consider interprofessional consultation.

The information was handed out by our drug information department via a drug-information sheet.

The data was recorded in an EXCEL sheet and updated upon each report from the manufacturers. Moreover, relevant changes had to be made depending on the classification of the DS (e.g. master-data-management, ward-order-system, Kanban-system, handling instructions) in order to ensure the DSC.

Results Between 1 January 2018 and 30 June 2018, 273 DS were recorded. Existing DS from 2016/2017 (38) were also included. One-hundred and seventy were resolved by 1 July 2018. Sixty-two were classified as red (critical or threatening to patient safety), 22 of which led to an interprofessional consultation. There was no alternative at all for five DS. Each consultation lasted 1 hour on average. Twenty-two of the recorded DS did not affect our clinic due to length and sufficient stock.

Conclusion The situation in everyday practice is so complex that standard procedures and interdisciplinary communication paths are necessary to manage DS in a way that does not impact the quality and continuity of patient care. Therefore, restrictions on therapeutic alternatives need to be determined and the close collaboration among pharmacists, nurses and physician is inevitable.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No references.

No conflict of interest.

2SPD-016

BIOSIMILARS OF INFlixIMAB AND RITUXIMAB: DOES THE INITIAL STRATEGY OF SELECTION HELP THEIR PRESCRIPTIONS?

C Beyron*, L Maljean, M Saglio, AS Leromain, C Jarre, M Hellot-Guersing, A Gadot, C Derharoutunian, R Roubille. Centre Hospitalier Lucien Hessel, Pharmacy Department, 38200 Vienne, France

10.1136/ejhp-2019-eahpconf.56

Background The development of biological medicines (BM) was a major step in the treatment of chronic diseases and cancer. However, their high costs are a financial issue for hospitals. The arrival of biosimilar drugs (BD) improved their accessibilities by reducing their prices. Nevertheless, in France, their consumption is still low.

Purpose The purpose of the study was to measure and analyse the penetration rate (PR) of biosimilar Infliximab and

biosimilar Rituximab in hospitals containing 300 to 700 beds in Auvergne Rhône Alpes (France).

Material and methods A web survey was sent to hospital pharmacists dispensing Infliximab and/or Rituximab to collect: consumption of Infliximab and Rituximab (biological reference products (BRM) and BD) in the first 6 months of 2018; initiation and switching strategy of BD; and education tools provided by pharmacists to patients and/or healthcare professionals. The PR was defined as the percentage of biosimilars of the total of BM. The web survey was online for 1 month.

Results Seven hospitals replied to the survey: all were consumers of Infliximab and four were consumers of Rituximab. The PR of biosimilar Infliximab was around 50% for two hospitals, around 30% for three hospitals and two hospitals did not use BD. The seven hospitals adopted the same initiation and switching strategy: biosimilar Infliximab was prescribed only for BM-naïve patients and continuous therapy could be switched with doctor's agreement.

Concerning Rituximab, the PR was 100% for two hospitals, 70% for one hospital and 40% for one hospital. All four hospitals concerned reported using the same strategy: switch from the BRM to the BD for every patient. The recent introduction of Rituximab biosimilar in the French market could explain the 2 PR lower than 100%.

Concerning education provided by pharmacists about BD, all had a different strategy (education to patient, to doctor, presentation in drug committee...).

Conclusion Although these hospitals adopted the same strategy of biosimilar selection, the PR were significantly different from one hospital to another. None of the education tools provided was linked to a greater biosimilar penetration. The consensus of national societies and expert recommendations should help pharmacists to convince prescribers.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

2SPD-017

ECHO-ENDOSCOPY: FOR A SOURCING AS SHARP AS A NEEDLE

¹MA Bildan*, ¹O Chauvel, ²JP Farmachidi, ¹JL Pons, ¹L Nicolas. ¹Centre Hospitalier Victor Dupouy, Pharmacy, Argenteuil, France; ²Centre Hospitalier Victor Dupouy, Gastrointestinal Endoscopy, Argenteuil, France

10.1136/ejhp-2019-eahpconf.57

Background In April 2018, the acquisition of two echo-endoscopes enabled the deployment of a new activity within the hospital centre. Echo-endoscopy is an act of exploration combining ultrasound with endoscopy, which allows, using specific needles, the realisation of sampling and therapeutic drainages.

Purpose Therefore, we compared the different market-available needles.

Material and methods Three providers (A, B, C), previously selected in a regional framework agreement, were solicited for new quotations and specimens. A technical sheet was designed evaluating: quality of packaging and labelling; composition of the kit; characteristics of the needles (dimensions, materials, fenestrated or not, echogenicity, penetration, graduation accuracy, grip, diameter compatibility with the working channel); and quality of the samples obtained. The scores of each supplier were calculated with a weighting of 80% for the quality and 20% for the price.